Analysis of ABO System Hemolytic Disease of the Newborn in 283 Cases at Yunnan Province.
10.19746/j.cnki.issn.1009-2137.2025.03.039
- Author:
Jin-Yu ZHOU
1
;
Ru SHEN
1
;
Han-Xin WU
2
;
Ju-Ding GUO
1
;
Hong-Mei LIU
1
;
Li-Li SHU
1
;
Yu ZHU
1
;
Jing-Yue SUN
1
;
Jun CHANG
1
Author Information
1. Department of Clinical Laboratory Examination, Matemal and Child Health Hospital of Kunming, Kunming 650101, Yunnan Province, China.
2. Faculty of Basic Medical Science, Kunming Medical University, Kunming 650500, Yunnan Province, China.
- Publication Type:Journal Article
- Keywords:
ABO incompatibility;
hemolytic disease of fetus and newborn;
direct anti human globulin test;
antibody release test;
free antibody test
- MeSH:
Humans;
Infant, Newborn;
ABO Blood-Group System;
Erythroblastosis, Fetal/epidemiology*;
Female;
China/epidemiology*;
Blood Group Incompatibility;
Male;
Bilirubin/blood*
- From:
Journal of Experimental Hematology
2025;33(3):881-885
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the laboratory detection results of hemolytic disease of the fetus and newborn(HDFN).
METHODS:Related test results of 283 newborns and their mothers' blood samples from Kunming Maternal and Child Health Hospital from August 2023 to May 2024 were collected, including mother and child ABO blood group, RhD blood group, as well as 3 tests of HDFN, total bilirubin (TBil) and indirect bilirubin (IBil).
RESULTS:283 were ABO incompatibility, among which 187 were HDFN positive, with a positive rate of 66.08%; the positive rate of HDFN in neonates with antigen-A incompatibility was 74.12%(126/170), the positive rate of HDFN in neonates with antigen-B incompatibility was 53.57%(60/112), which was the highest in neonates with O/A incompatibility ［75.45%(126/167)］, followed by O/B incompatibility［54.55%(60/110)］. Group by age, the positive rates of HDFN in the ≤1 d group, 2 d group, 3 d group, 4 d group, 5 d group and ≥6 d group were 76.03%(111/146), 67.86%(38/56), 57.14%(24/42), 38.46%(5/13), 46.15%(6/13) and 23.08%(3/13), respectively. With the increase of age, the positive rates of HDFN gradually decreased, there was a statistically significant difference between the ≤3 day age group and >3 day age group ( P <0.05). There was no statistically significant difference in TBil and IBil levels between the "direct antibody+indirect antibody+release+" group and the HDFN negative group in newborns. HDFN infants exhibited a rapid increase in bilirubin levels within the first day after birth, with significantly higher TBil and IBil values compared to Non ABO-HDFN infants in the ≤1 day group ( P <0.01). However, the difference of bilirubin levels between the two groups gradually narrowed from 2-6 days after birth, and the difference was not statistically significant (P >0.05). The peak value of TBil and IBil occurred on the 4th day after birth in HDFN infants.
CONCLUSION:ABO-HDFN is most commonly seen in newborns whose mothers are type-O, and the positive rate was the highest in newborns with O/A incompatibility. The detection rate of HDFN is affected by the age of the newborns, and the two were correlated inversely. ABO-HDFN group developed more rapidly with a higher peak. Therefore, HDFN tests should be carried out as soon as possible for mothers and newborns with incompatible blood types, and appropriate treatment should be provided to prevent complications.
